- Full-scale development of novel drugs for biliary tract cancer, brain disorders, and metabolic diseases
- Emphasis on next-generation pipeline and 바카라 전략 initiatives of affiliates
[by Ji, Yong Jun] HLB convened the ‘HLB Forum’ on May 22, bringing together its group affiliates to discuss and align on the organization’s future strategic direction. Now in its third year, the HLB Forum has evolved beyond its original focus as an R&D-oriented bio forum, repositioning itself as a broader strategic platform encompassing a wider array of corporate development initiatives.
Held under the theme ‘2025 Leap, 2030 Emergency: Drawing the Future of 바카라 전략,’ the forum presented the current development status of 바카라 전략 Group’s core pipelines driving its growth, alongside strategic pipelines envisioned for future advancement. In addition, the event outlined key business plans centered on a ‘diagnosis-prevention-treatment’ framework in preparation for the 2030 emergency and detailed the group’s open innovation investment strategy.
In his opening address at the forum, 바카라 전략 Chairman Jin Yang-gon stated, “As a Korean biopharmaceutical company, we are committed to forging an ‘untraveled’ path with the determination to independently manage every stage, from development and clinical trials to regulatory approval and commercialization, with the aim of establishing ourselves as a global leader in anticancer therapeutics.”
The forum’s first lecture was delivered by Chong Sae-ho, CEO of Elevar Therapeutics, who provided an overview of the development and global regulatory approval process for the 바카라 전략 Group’s core pipeline, ‘rivoceranib + camrelizumab combination therapy,’ for the treatment of hepatocellular carcinoma. Additionally, he discussed the rationale behind the introduction of ‘lirafugratinib (RLY-4008),’ a cholangiocarcinoma candidate, as a follow-up pipeline to rivoceranib, highlighting its strategic importance.
“Lirafugratinib is a highly selective oral treatment agent targeting fibroblast growth factor receptor type 2 (FGFR2) fusion, mutation, and amplification. We have identified it as a pipeline candidate with the potential to become a global first-in-class innovative new drug for solid tumors with limited treatment options, including cholangiocarcinoma,” Chong said.
The second presentation was delivered by Professor Richard Kim of the Moffitt Cancer Center in the United States, who participated in the Phase 1 and 2 clinical trials of lirafugratinib. He provided an overview of the current treatment paradigm for cholangiocarcinoma, emphasizing the use of combination immunotherapy as a first-line treatment, and discussed the 바카라 전략 application of second-line targeted therapies for patients harboring FGFR2 mutations.
“Lirafugratinib is the first highly selective irreversible inhibitor that specifically targets FGFR2, thereby minimizing side effects commonly associated with existing pan-FGFR inhibitors and demonstrating efficacy against resistant mutations,” Richard Kim expressed. “It has shown promise as a next-generation FGFR2-targeted treatment, achieving an objective response rate (ORR) of 바카라 전략 to 88.2% in FGFR2 fusion cholangiocarcinoma patients who have not previously received FGFR inhibitor treatment,” he added.
Following the forum, key affiliates of the 바카라 전략 Group, including 바카라 전략 Genex, 바카라 전략 NeuroTobe, and 바카라 전략 PEP, held press conferences to showcase their technological capabilities and outline their strategic directions. Kim Do-yeon, CEO of 바카라 전략 Genex, emphasized, “We possess platform technology capable of rapidly developing and cost-effectively mass producing industrial enzymes like catalase and lactase,” adding, “Our technological capabilities are being validated through supply to global semiconductor and dairy companies.” He went on to outline a sustainable growth plan strategy centered on portfolio expansion into cosmetics, health functional foods, and diagnostic enzymes, alongside stable revenue growth from core products and the reinforcement of B2C (business-to-consumer) operations through technological collaboration with other group affiliates.
Kim Dae-soo, CEO of 바카라 전략 NeuroTobe, introduced the company’s core pipeline assets, ‘NT-1,’ a treatment candidate for dystonia, and ‘NT-3,’ a candidate for a treatment of Parkinson’s disease. “NT-1 represents a novel treatment mechanism in the treatment of dystonia, a condition for which existing treatment options are extremely limited, and is aimed at addressing significant unmet needs in the rare neurological disease market. Regarding NT-3, this antisense oligonucleotide (ASO) therapy targets both symptomatic relief and neuronal cell death in Parkinson’s disease and is regarded as an innovative novel drug candidate with the potential to be effective in mid- to late-stage patients,” Kim explained.
CEO Shim Kyung-jae of 바카라 전략 PEP introduced the company by highlighting its foundation on a proprietary library of approximately 5,000 peptides and unrivaled peptide synthesis technology, which collectively underpin its competitiveness in various fields, including active pharmaceutical ingredients (API), contract development and manufacturing (CDMO), and cosmetics. Shim further emphasized the company’s strategic focus on peptide-based therapeutics, stating that with a robust pipeline targeting metabolic diseases such as obesity and diabetes, as well as ulcerative colitis, 바카라 전략 PEP aims to lead the global peptide healthcare market by securing cGMP certification and advancing the development of high value-added novel therapeutics.